|
Lupus Erythematosus, Systemic
|
0.280 |
Biomarker
|
disease |
BEFREE |
To evaluate the expression of the cytokines BAFF and APRIL and their association with the receptors BAFF-R and TACI on CD3+ T cells and to evaluate Th1/Th2/Th17 cytokine profile in patients with SLE.
|
30467093 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.280 |
Biomarker
|
disease |
BEFREE |
We showed that BAFF could induce IL-35 production by a unique CD5<sup>+</sup>CD1d<sup>hi</sup>FcγRIIb<sup>hi</sup> regulatory B-cell subset mainly through TACI activation in lupus, providing an advanced understanding of the regulatory effect of BAFF in autoimmune diseases.
|
28844943 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.280 |
Biomarker
|
disease |
BEFREE |
A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
|
28383107 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.280 |
AlteredExpression
|
disease |
BEFREE |
Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
|
26424128 |
2016 |
|
Lupus Erythematosus, Systemic
|
0.280 |
Biomarker
|
disease |
BEFREE |
Therefore, B cell-sparing blockade of TACI may offer a more specific and safer therapeutic alternative to broad B cell depletion in SLE.
|
26027434 |
2015 |
|
Lupus Erythematosus, Systemic
|
0.280 |
Biomarker
|
disease |
BEFREE |
To compare skin and blood mRNA and protein levels of BAFF and its receptors BAFF-R, TACI, and BCMA in DLE subjects with (DLE+/SLE+ (N=28)) and without SLE (DLE+/SLE- (N=35)), psoriasis subjects (N=11), and normal subjects (N=42).
|
24315762 |
2014 |
|
Lupus Erythematosus, Systemic
|
0.280 |
Biomarker
|
disease |
BEFREE |
TACI-Ig suppressed spontaneous in vitro T cell-dependent B cell anti-dsDNA antibodies production on active SLE with kidney involvement.
|
17500077 |
2007 |
|
Lupus Erythematosus, Systemic
|
0.280 |
Biomarker
|
disease |
BEFREE |
Based on our recent finding that TACI is mutated in patients with common variable immunodeficiency, of whom more than 30% suffer from autoimmune conditions, we analyzed TACI in humans with SLE.
|
17464555 |
2007 |
|
Lupus Erythematosus, Systemic
|
0.280 |
Biomarker
|
disease |
MGD |
Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor.
|
12594954 |
2003 |
|
Lupus Erythematosus, Systemic
|
0.280 |
Biomarker
|
disease |
MGD |
Activation and accumulation of B cells in TACI-deficient mice.
|
11429549 |
2001 |